Arm stock surged 157% since IPO, CEO sees AI as key to smartphone and PC market growth Arm targets 50% of Windows PC market, boosts AI role in OpenAI's $100B Stargate project Get two weeks of free ...

Below is Validea's guru fundamental report for ARM HOLDINGS PLC - ADR (ARM). Of the 22 guru strategies we follow, ARM rates highest using our Quantitative Momentum Investor model based on the ...

Year to date, AstraZeneca registers a 13.0% gain. And the worst performing Nasdaq 100 component thus far on the day is Arm Holdings, trading down 7.4%. Arm Holdings is showing a gain of 30.1% ...

NASDAQ ARM opened at $157.74 on Monday. The company’s fifty day moving average price is $145.10 and its two-hundred day moving average price is $139.72. ARM has a 12 month low of $85.61 and a 12 ...

ARM Stock Performance ARM opened at $162.51 on Friday. Arm Holdings plc has a one year low of $85.61 and a one year high of $188.75. The stock’s fifty day moving average is $144.13 and its 200 ...

Arm Holdings (NASDAQ:ARM) has withdrawn a threat to terminate an architecture license agreement with Qualcomm (NASDAQ:QCOM), Qualcomm’s chief executive officer Cristiano Amon said in a post ...

Renaissance Technologies took a new stake in Intel (INTC) and exited its position in Arm (ARM) in Q4 2024. Read more here.

Nasdaq Inc. Chief Executive Officer Adena Friedman said she expects a strong environment for initial public offerings in the second quarter and balance of 2025 as investors gain confidence from ...

Arm Holdings Plc gave a cautious revenue forecast for the current period, adding to recent concern that spending on artificial intelligence computing is slowing. Revenue will be $1.18 billion to $ ...

The primary market is all set to take a breather as no new initial public offering (IPO) is set to open in the mainboard segment. Last week, Dr Agarwal's Health IPO, which closed for subscription ...

ARM stock is in a strong bullish trend, trading above key moving averages ahead of Q3 earnings. Analysts maintain a bullish rating but see a 7% downside from current levels based on price targets ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...